The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant Entitled "Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum"

 

Doylestown, PA. April 20, 2021 - FCCDC is pleased to announce that it has been awarded a new Phase I STTR (R41AI162385) entitled "Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum" with Prof. Rob Ricciardi of the University of Pennsylvania as the Principal Investigator.